Reiberger, Thomas http://orcid.org/0000-0002-4590-3583
Berzigotti, Annalisa
Trebicka, Jonel
Ertle, Judith
Gashaw, Isabella
Swallow, Ros
Tomisser, Andrea
Funding for this research was provided by:
Boehringer Ingelheim
Article History
Received: 10 December 2022
Accepted: 3 April 2023
First Online: 24 April 2023
Declarations
:
: The trials will be initiated at the respective study sites only after all required legal documentation has been reviewed and obtained, and the study protocol has been reviewed and approved by the responsible IRB/IEC at both central and local levels. The same applies for the implementation of changes introduced by amendments. Receipt of signed and dated informed consent represents inclusion criteria for the trial. A trial investigator or delegate will obtain informed, freely given, written consent from each subject via a consent form, after confirming that the subject understands the study design and the content of the form.
: All authors consent to the publication of this article. The Boehringer Ingelheim transparency and publication policy can be found on the following web page: trials.boehringer-ingelheim.com. The consent documents are available from the corresponding author on request.
: TR has received grant support from AbbVie, Boehringer Ingelheim, Gilead Sciences, Gore, Intercept Pharmaceuticals, MSD, MYR Pharmaceuticals, Philips Healthcare, Pliant and Siemens; speaking honoraria from AbbVie, Gilead Sciences, Gore, Intercept Pharmaceuticals, MSD and Roche; consulting or advisory board fees from AbbVie, Bayer, Boehringer Ingelheim, Gilead Sciences, Intercept Pharmaceuticals, MSD and Siemens; and travel support from AbbVie, Boehringer Ingelheim, Gilead Sciences and Roche. AB has been an advisory board member for Inventiva, Bracco, General Electrics, and Boehringer Ingelheim. JT has received speaking and/or consulting fees from Versantis, Gore, Boehringer-Ingelheim, Alexion, Falk, Mallinckrodt, Grifols and CSL Behring and was supported by the German Research Foundation (DFG) project ID 403224013 – SFB 1382 (A09), by the German Federal Ministry of Education and Research (BMBF) for the DEEP-HCC project and by the Hessian Ministry of Higher Education, Research and the Arts (HMWK) for the ENABLE and ACLF-I cluster projects. The MICROB-PREDICT (project ID 825694), DECISION (project ID 847949), GALAXY (project ID 668031), LIVERHOPE (project ID 731875) and IHMCSA (project ID 964590) projects have received funding from the European Union’s Horizon 2020 research and innovation programme. JE, IG, RS and AT are employees of Boehringer Ingelheim. The manuscript reflects only the authors’ views, and the European Commission is not responsible for any use that may be made of the information it contains. The funders had no influence on the study design, data collection and analysis, decision to publish, or preparation of the manuscript.